

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

Brilliant Violet 510(TM) anti-human CD8a

RRID:AB_2561942

Type: Antibody

Proper Citation

BioLegend Cat# 301048, RRID:AB_2561942

Antibody Information

URL: http://antibodyregistry.org/AB_2561942

Proper Citation: BioLegend Cat# 301048, RRID:AB_2561942

Target Antigen: CD8alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD8a

Description: This monoclonal targets CD8alpha

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone RPA-T8

Antibody ID: AB_2561942

Vendor: BioLegend

Catalog Number: 301048

Alternative Catalog Numbers: 301047

Record Creation Time: 20250820T003514+0000

Record Last Update: 20250820T083947+0000

Ratings and Alerts

- Used for immunohistochemistry by the Human Islet Research Network community.
Contact(s): [James Riley](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Brilliant Violet 510(TM) anti-human CD8a.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mantus GE, et al. (2025) Distinct binding modes drive the broad neutralization profile of two persistent influenza hemagglutinin stem-specific antibody lineages. *Structure (London, England : 1993)*, 33(5), 869.

Chauhan SKS, et al. (2025) Protocol for optimized mononuclear cell isolation from liver and tumor tissue using mechanical or enzymatic digestion. *STAR protocols*, 7(1), 104289.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. *iScience*, 28(5), 112497.

Schweihofer V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1622008.

Petrov L, et al. (2025) Rewired type I IFN signaling is linked to age-dependent differences in COVID-19. *Cell reports. Medicine*, 6(8), 102285.

Papadimitriou TI, et al. (2025) CD8+ T cells drive myofibroblast activation and contraction via JAK/STAT3 and TGF β signaling. *iScience*, 28(12), 113904.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ . *Cell*, 187(5), 1238.

Nesamari R, et al. (2024) Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 162.

Benede N, et al. (2024) Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity. *iScience*, 27(1), 108728.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- β 1 and IL-2 confer immunoregulatory functions to NK cells. *iScience*, 27(12), 111416.

Lanman NA, et al. (2024) Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. *Frontiers in immunology*, 15, 1494476.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Hudson WH, et al. (2023) Immune microenvironment remodeling after radiation of a progressing brain metastasis. *Cell reports. Medicine*, 4(6), 101054.

Moore SC, et al. (2023) Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. *Med (New York, N.Y.)*, 4(3), 191.

Saotome K, et al. (2023) Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM. *Nature communications*, 14(1), 2401.

Keeton R, et al. (2023) Impact of SARS-CoV-2 exposure history on the T cell and IgG response. *Cell reports. Medicine*, 4(1), 100898.

Pinto C, et al. (2023) Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics. *iScience*, 26(4), 106381.

du Bruyn E, et al. (2023) Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. *Nature communications*, 14(1), 188.

Ellis GI, et al. (2022) Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in *Cynomolgus* macaque. *Cell reports. Medicine*, 3(5), 100614.

Koutsakos M, et al. (2022) The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. *Immunity*, 55(7), 1316.